Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Nature - 12 Oct 2017

Kong Xiangjun, Kuilman Thomas, Shahrabi Aida, Boshuizen Julia, Kemper Kristel, Song Ji-Ying, Niessen Hans W M, Rozeman Elisa A, Geukes Foppen Marnix H, Blank Christian U, Peeper Daniel S

Abstract excerpt

Observations from cultured cells, animal models and patients raise the possibility that the dependency of tumours on the therapeutic drugs to which they have acquired resistance represents a vulnerability with potential applications in cancer treatment. However, for this drug addiction trait to become of clinical interest, we must first define the mechanism that underlies it. We performed an unbiased CRISPR-Cas9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Death
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Gene Editing

Share to MAP Kinase Signaling System

Share to Microphthalmia-Associated Transcription Factor

Share to Mitogen-Activated Protein Kinase 1

Share to Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 28976960
DOI: 10.1038/nature24037
PMCID: PMC5640985

Genes

BRAF
MITF
AXL
JUNB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.PMID 28976960Read ↗

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant MelanomaSemantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

Cancer therapy based on oncogene addictionSemantic proximity Read ↗

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Drugging the addict: non-oncogene addiction as a target for cancer therapy.Semantic proximity Read ↗

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.Semantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFSemantic proximity Read ↗

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanomaSemantic proximity Read ↗

Directed phenotype switching as an effective antimelanoma strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.